Table 1.

Main characteristics of included articles

First author	Year	Trial group				Control group				Outcomes
		Therapy	n	Male/female	Age	Therapy	n	Male/female	Age
Han[15]	2017	HP+HF+Con	11	6/5	38.7±4.3	HP+Con	13	7/6	38.1±4.2	➀➁➂➃➄
Jiao[16]	2016	HP+HF+Con	37	14/23	41.9±5.1	HP+Con	37	17/20	42.1±5.2	➀➃➄
Liu[17]	2016	HP+HF+Con	17	9/8	43.1±8.0	HP+Con	17	10/7	42.9±8.3	➀➁➂➃➄
Wang[18]	2016	HP+HF+Con	60	21/39	68.5±5.3	HP+Con	60	21/39	68.5±5.3	➀➂➃
Xia[19]	2013	HP+HF+Con	34	12/22	45.5±9.1	Con	32	12/20	46.5±8.2	➀➁➄
Xie[20]	2019	HP+HF+Con	55	30/25	44.4±4.7	HP+Con	55	32/23	44.5±4.8	➀➁➃➄
Xu[21]	2014	HP+HF+Con	34	12/22	36.2±2.3	Con	32	11/21	35.6±7.4	➀➂➃➄
Xue[22]	2019	HP+HF+Con	31	10/21	66.7±6.2	HF+Con	31	12/19	67.5±5.3	➀➃➄
Yang[23]	2014	HP+HF+Con	41	19/22	38.5±6.2	HP+Con	40	17/23	37.8±3.6	➀➃
Yang[24]	2016	HP+HF+Con	32	24/8	40.5±3.2	Con	30	25/5	40.4±3.3	➀➃➄
Yue[25]	2015	HP+HF+Con	56	24/32	43.2±8.4	Con	56	28/28	44.3±8.2	➂➃➄

Outcomes: ➀=mortality; ➁=atropine dosing; ➂=duration of mechanical ventilation; ➃=restoration time of cholinesterase; ➄=length of stay. HP=Hemoperfusion; HF=Hemofiltration; Con=Conventional